Nkarta, Inc. SEC filings NKTX

Nkarta, Inc. has 438 filings in SEC EDGAR's recent list, going back to Sep 6, 2019. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 23, 2026 —
DEF 14A Proxy statement Apr 23, 2026 Jun 10, 2026
DEFA14A Additional proxy material Apr 21, 2025 —
DEF 14A Proxy statement Apr 21, 2025 Jun 5, 2025
DEFA14A Additional proxy material Apr 25, 2024 —
DEF 14A Proxy statement Apr 25, 2024 Jun 13, 2024
PRE 14A Preliminary proxy statement Apr 15, 2024 Jun 13, 2024
DEFA14A Additional proxy material Apr 24, 2023 —
DEF 14A Proxy statement Apr 24, 2023 Jun 7, 2023
PRE 14A Preliminary proxy statement Apr 14, 2023 Jun 7, 2023
DEFA14A Additional proxy material Apr 21, 2022 —
DEF 14A Proxy statement Apr 21, 2022 Jun 8, 2022
DEFA14A Additional proxy material Apr 22, 2021 —
DEF 14A Proxy statement Apr 22, 2021 Jun 11, 2021

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NKTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1787400

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.